Furthermore, suppression of GPX4 and SOD2 reversed resistance to EGFR-TKIs in NSCLC [25] and the induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin [26]. The gene discussed is EGFR; the disease is osteosarcoma.